Correspondence 0001607062-23-000444 from Regen BioPharma Inc (RGBP)

Regen BioPharma Inc
Date: Sept. 27, 2023 · CIK: 0001589150 · Accession: 0001607062-23-000444

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-274675

Date

September 25, 2023

Author

David R.Koos

Form

CORRESP

Company

Regen BioPharma Inc

Letter

United States Securities and Exchange Commission Division of Corporation Finance Attention: Dillon Hagius Registration Statement on Form S-1 Filed September 25, 2023 File No. 333-274675

Re: Regen Biopharma, Inc.

Dear Mr. Hagius

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Regen Biopharma, Inc.., a Nevada corporation (the “Company”), hereby requests that the effectiveness of its Registration Statement on Form S-1, as amended (Registration No. 333-274675), be accelerated so that it will become effective at 9:00 AM Eastern Standard Time on September 29, 2023 or as soon thereafter as practicable.

The Company hereby acknowledges that:

• Should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

• The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

• The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very
truly yours,
/s/
David R.Koos

Show Raw Text

CORRESP
1
filename1.htm

September
27, 2023

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, NE

Washington,
DC 20549

Attention:
Dillon Hagius

Re:
Regen Biopharma, Inc.

Registration
Statement on Form S-1

Filed
September 25, 2023

File No.
333-274675

Dear
Mr. Hagius

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Regen Biopharma, Inc.., a Nevada corporation
(the “Company”), hereby requests that the effectiveness of its Registration Statement on Form S-1, as amended (Registration
No. 333-274675), be accelerated so that it will become effective at 9:00 AM Eastern Standard Time on September 29, 2023 or as soon thereafter
as practicable.

The
Company hereby acknowledges that:

•  Should
                                            the Securities and Exchange Commission (the “Commission”) or the staff, acting
                                            pursuant to delegated authority, declare the filing effective, it does not foreclose the
                                            Commission from taking any action with respect to the filing;

•  The
                                            action of the Commission or the staff, acting pursuant to delegated authority, in declaring
                                            the filing effective, does not relieve the Company from its full responsibility for the adequacy
                                            and accuracy of the disclosure in the filing; and

•  The
                                            Company may not assert staff comments and the declaration of effectiveness as a defense in
                                            any proceeding initiated by the Commission or any person under the federal securities laws
                                            of the United States.

Very
truly yours,

/s/
David R.Koos

David
R. Koos,

Chairman&
CEO

SecProbe.io